Lipocine (LPCN)
Develops oral therapies and licenses approved testosterone product TLANDO to commercialization partners.
$2.39
At close+0.09 (+3.91%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions46 holders · as of Mar 31, 2026 | 37.83% | 3.12M shares | |
| Insiders2 holders · as of Apr 7, 2026 | 4.42% | 364.5K shares | |
| Otherremainder | 57.75% | 4.76M shares |
8.24M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
46 holders · 3.12M shares · 24 new positions · 33 increased · 9 reduced · 4 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ikarian Capital, LLC | 508.6K | 6.17% | +309.0K | May 15, 2026 |
| Squadron Capital Management LLC | 450.0K | 5.46% | −80.0K | May 15, 2026 |
| Eversept Partners, LP | 295.0K | 3.58% | +295.0Knew | May 15, 2026 |
| Rosalind Advisors, Inc. | 221.6K | 2.69% | +221.6Knew | May 14, 2026 |
| Vanguard Capital Management LLC | 200.7K | 2.43% | +200.7Knew | May 15, 2026 |
| Aigh Capital Management LLC | 200.0K | 2.43% | +200.0Knew | Apr 30, 2026 |
| Stempoint Capital LP | 160.4K | 1.95% | +160.4Knew | May 18, 2026 |
| Boothbay Fund Management, LLC | 140.5K | 1.70% | +85.6K | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Ikarian Capital, LLC | 6.30% | 508.6K | 13G | May 15, 2026 ↗ |
| Squadron Master Fund LP | 6.20% | 450.0K | 13G | May 15, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Apr 7, 2026 | John W. Higuchidirector | Purchase | 40,000 | $2.03 | 203,797 |
| Apr 6, 2026 | Mahesh V. Pateldirector, officer: Chief Executive Officer | Purchase | 25,000 | $2.03 | 160,679 |
| Apr 6, 2026 | John W. Higuchidirector | Purchase | 123,000 | $2.05 | 163,797 |
| Apr 2, 2026 | Mahesh V. Pateldirector, officer: Chief Executive Officer | Purchase | 25,000 | $2.02 | 135,679 |
CongressHouse and Senate disclosures
Not reported.
